Global Liquid Biopsy Market: Focus on Products and Services, Therapeutic Applications, Clinical Applications, Circulating Biomarkers, Country Analysis (16 Countries), Industry Insights, and Competitive Landscape - Analysis and Forecast, 2018-2028
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Tissue biopsy is the predominant diagnostic procedure that is used for cancer diagnosis and treatment monitoring. Tissue biopsy is essentially dependent on invasive surgical procedures which in many instances preclude the regular treatment monitoring and sometimes the initial diagnosis too. This has elevated the requirement for novel diagnostic approaches. The search for better minimal invasive diagnostic procedures aimed at aiding regular monitoring of a patient’s response toward the treatment resulted in the evolution of liquid biopsy tests. Recent research on cancer biomarkers’ presence in biological fluids, such as blood which can be collected through minimal invasive techniques, has yielded promising results to develop better minimal invasive diagnostics procedures known as liquid biopsy.
Liquid biopsy is a minimal invasive medical procedure with the ability to detect the presence of molecular cancer biomarkers in the biological fluids. The derived test results aid the doctors in deciding the further steps in the treatment of the patients suffering from cancer. The test principally involves the usage of samples of biological fluids, such as blood, urine, serum, and saliva, among others, and then the enrichment of the samples using different techniques, such as Next Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR), to detect the mutations known to cause cancer.
The purpose of this study is to gain a holistic view of the liquid biopsy market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the global liquid biopsy market. The market has been segmented into “Biomarker”, “Clinical Applications”, “Therapeutic Applications”, “Products and Services”, and “Region”. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
This research report aims at answering various aspects of the global liquid biopsy market, with the help of the key factors driving the market, restraints and challenges that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report also includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.
The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the global liquid biopsy market. Moreover, the study includes detailed product mapping, market estimation and analysis of key trends in multiple geographical regions, growth of liquid biopsy market in each region for different cancer types, and the key strategies and developments by the prominent liquid biopsy market stake holders.
The answers to the following key questions can be derived from this report:
Tissue biopsy is the predominant diagnostic procedure that is used for cancer diagnosis and treatment monitoring. Tissue biopsy is essentially dependent on invasive surgical procedures which in many instances preclude the regular treatment monitoring and sometimes the initial diagnosis too. This has elevated the requirement for novel diagnostic approaches. The search for better minimal invasive diagnostic procedures aimed at aiding regular monitoring of a patient’s response toward the treatment resulted in the evolution of liquid biopsy tests. Recent research on cancer biomarkers’ presence in biological fluids, such as blood which can be collected through minimal invasive techniques, has yielded promising results to develop better minimal invasive diagnostics procedures known as liquid biopsy.
Liquid biopsy is a minimal invasive medical procedure with the ability to detect the presence of molecular cancer biomarkers in the biological fluids. The derived test results aid the doctors in deciding the further steps in the treatment of the patients suffering from cancer. The test principally involves the usage of samples of biological fluids, such as blood, urine, serum, and saliva, among others, and then the enrichment of the samples using different techniques, such as Next Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR), to detect the mutations known to cause cancer.
The purpose of this study is to gain a holistic view of the liquid biopsy market in terms of various influencing factors, such as recent trends, regulatory frameworks, and technological advancements in the market. The scope of this report constitutes a detailed study of the different kinds of products associated with the global liquid biopsy market. The market has been segmented into “Biomarker”, “Clinical Applications”, “Therapeutic Applications”, “Products and Services”, and “Region”. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.
This research report aims at answering various aspects of the global liquid biopsy market, with the help of the key factors driving the market, restraints and challenges that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report also includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.
The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the global liquid biopsy market. Moreover, the study includes detailed product mapping, market estimation and analysis of key trends in multiple geographical regions, growth of liquid biopsy market in each region for different cancer types, and the key strategies and developments by the prominent liquid biopsy market stake holders.
The answers to the following key questions can be derived from this report:
- What are the key features of the liquid biopsy technology promoting its incorporation in different clinical applications?
- What are the key advantages of the liquid biopsy technology over tissue biopsy?
- How did the liquid biopsy market evolve and what is its scope in the future?
- What are the major market drivers, challenges, and opportunities in the global liquid biopsy market?
- What are the key developmental strategies which are implemented by the key players to stand out in this market?
- What are the leading companies dominating the global liquid biopsy market?
- Which therapeutic application market would witness massive incorporation of the liquid biopsy technology in the forecast period?
- Products based on which circulating biomarker are anticipated to witness massive rise in their demand in the forecast period?
- How would the scope of clinical application of the liquid biopsy technology evolve in the forecast period?
- What are investors’ perceptions about the global liquid biopsy market?
- Who are the leading stakeholders of the market holding significant share in the market’s intellectual property?
- What are the key companies which made substantial investments to aid technological advancements in the market?
- What are the regulations pertaining to the global liquid biopsy market?
- What are initiatives implemented by different government bodies to combat the growing prevalence of different types of cancer?
- What was the market value of the leading segments and sub-segments of the global liquid biopsy market?
- How will each segment of the global liquid biopsy market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028?
- How will the industry evolve during the forecast period 2018-2028?
- Which geographical location will contribute to the highest sales of the global liquid biopsy market during the forecast period?
EXECUTIVE SUMMARY
1 MARKET OVERVIEW
1.1 Historical Trends
1.2 Comparative Analysis of Tissue Biopsy and Liquid Biopsy
1.3 Clinical Applications of Liquid Biopsy
1.4 Trends for Liquid Biopsy
1.5 Assumptions and Limitations for Market Size Calculations
1.6 Global Liquid Biopsy Market Scenario
2 MARKET DYNAMICS
2.1 Impact Analysis
2.2 Market Drivers
2.2.1 Potential of Liquid Biopsy
2.2.2 Ability to Monitor Clonal Mutations
2.2.3 Growing Prominence of Precision Medicine
2.3 Market Restraints
2.3.1 Uncertain Reimbursement and Regulatory Policies
2.3.2 High Pricing Pressure
2.3.3 Adoption of Traditional Diagnosis Practices
2.4 Market Opportunities
2.4.1 Development of Medication Package Deals
2.4.2 Expansion into Emerging markets
2.4.3 Scope of Liquid Biopsy for Intervention: Diagnosis of Non-oncology Disorders
3 COMPETITIVE INSIGHTS
3.1 Key Strategies and Developments
3.1.1 Mergers and Acquisitions
3.1.2 Business Expansions
3.1.3 Awards, Recognitions, Certifications, and Others
3.1.4 Product Launches and Enhancements
3.1.5 Joint Ventures, Partnerships, and Collaborations
3.2 Market Share Analysis
3.3 Growth Share Analysis
3.3.1 Growth Share Analysis (by Prominent Companies)
3.3.2 Growth Share Analysis (by Therapeutic Application)
3.3.3 Growth Share Analysis (by Biomarker Type)
3.3.4 Growth Share Analysis (by Clinical Application)
3.4 Global Comprehensive Competitive Index (CCI)
3.5 Industry Attractiveness
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyer
3.5.3 Threat of New Entrants
3.5.4 Threat of Substitute Products
3.5.5 Intensity of Competitive Rivalry
4 INDUSTRY INSIGHTS
4.1 Introduction
4.2 Patent Analysis
4.3 Funding Scenario
4.4 Regulatory Bodies
4.5 Clinical Laboratory Improvement Amendments (CLIA) Program
4.6 Government Initiatives
5 GLOBAL LIQUID BIOPSY MARKET (BY CIRCULATING BIOMARKERS)
5.1 Circulating Tumor DNA (cTDNA)
5.2 Circulating Tumor Cells (CTCs)
5.3 Cell-Free DNA (cfDNA)
5.4 Extracellular Vesicles and Others
6 GLOBAL LIQUID BIOPSY MARKET (BY PRODUCTS)
6.1 Tests/Services
6.2 Kits and Consumables
6.3 Instruments
7 GLOBAL LIQUID BIOPSY MARKET (BY THERAPEUTIC APPLICATION)
7.1 Lung Cancer
7.2 Breast Cancer
7.3 Prostate Cancer
7.4 Colorectal Cancer
7.5 Melanoma Cancer
7.6 Other Types of Cancer
7.7 Non-Oncology Application
8 GLOBAL LIQUID BIOPSY MARKET (BY CLINICAL APPLICATIONS)
8.1 Treatment Monitoring
8.2 Prognosis and Reoccurrence Monitoring
8.3 Treatment Selection
8.4 Diagnosis and Screening
9 GLOBAL LIQUID BIOPSY MARKET (BY REGION)
9.1 Analysis of Growth Potential of Different Countries: Global Liquid Biopsy Market
9.1.1 Cluster-1: China and India
9.1.2 Cluster-2: The U.S. and Japan
9.1.3 Cluster-3: Brazil, South Korea, Spain, Italy, The U.K., France, and Canada
9.1.4 Cluster-4: Germany, Australia, Singapore, Mexico, and Saudi Arabia
9.2 North America
9.2.1 The U.S.
9.2.1.1 U.S. Liquid Biopsy Market (by Therapeutic Application)
9.2.2 Canada
9.2.2.1 Canada Liquid Biopsy Market (by Therapeutic Application)
9.3 Europe
9.3.1 Germany
9.3.1.1 Germany Liquid Biopsy Market (by Therapeutic Application)
9.3.2 France
9.3.2.1 France Liquid Biopsy Market (by Therapeutic Application)
9.3.3 The U.K.
9.3.3.1 U.K. Liquid Biopsy Market (by Therapeutic Application)
9.3.4 Italy
9.3.4.1 Italy Liquid Biopsy Market (by Therapeutic Application)
9.3.5 Spain
9.3.5.1 Spain Liquid Biopsy Market (by Therapeutic Application)
9.3.6 Rest-of-Europe
9.4 Asia-Pacific
9.4.1 China
9.4.1.1 China Liquid Biopsy Market (by Therapeutic Application)
9.4.2 Japan
9.4.2.1 Japan Liquid Biopsy Market (by Therapeutic Application)
9.4.3 India
9.4.3.1 India Liquid Biopsy Market (by Therapeutic Application)
9.4.4 Australia
9.4.4.1 Australia Liquid Biopsy Market (by Therapeutic Application)
9.4.5 South Korea
9.4.5.1 South Korea Liquid Biopsy Market (by Therapeutic Application)
9.4.6 Singapore
9.4.6.1 Singapore Liquid Biopsy Market (by Therapeutic Application)
9.4.7 Rest-of-Asia-Pacific
9.5 Latin America and Middle East
9.5.1 Brazil
9.5.1.1 Brazil Liquid Biopsy Market (by Therapeutic Application)
9.5.2 Mexico
9.5.2.1 Mexico Liquid Biopsy Market (by Therapeutic Application)
9.5.3 Saudi Arabia
9.5.3.1 Saudi Arabia Liquid Biopsy Market (by Therapeutic Application)
9.5.4 Rest-of-Latin America and Middle East
9.6 Rest-of-the-World
10 COMPANY PROFILES
10.1 Overview
10.2 Abcodia Ltd.
10.2.1 Company Overview
10.2.2 Role of Abcodia Ltd. in the Liquid Biopsy Market
10.2.3 SWOT Analysis
10.3 Adaptive Biotechnologies
10.3.1 Company Overview
10.3.2 Role of Adaptive Biotechnologies Corporation in the Liquid Biopsy Market
10.3.3 SWOT Analysis
10.4 ANGLE plc
10.4.1 Company Overview
10.4.2 Role of ANGLE plc in the Liquid Biopsy Market
10.4.3 Financials
10.4.3.1 Key Insights on the Financial Health of the Company
10.4.4 Global Presence
10.4.5 SWOT Analysis
10.5 Biocept, Inc.
10.5.1 Company Overview
10.5.2 Role of Biocept, Inc. in Liquid Biopsy Market
10.5.3 Financials
10.5.4 Key Insights about Financial Health of the Company
10.5.5 SWOT Analysis
10.6 Bio-Rad Laboratories, Inc.
10.6.1 Company Overview
10.6.2 Role of Bio-Rad Laboratories, Inc. in Liquid Biopsy Market
10.6.3 Financials
10.6.4 Key Insights about Financial Health of the company
10.6.5 Global Presence
10.6.6 SWOT Analysis
10.7 Cynvenio Biosystems, Inc.
10.7.1 Company Overview
10.7.2 Role of Cynvenio Biosystems, Inc. in the Liquid Biopsy Market
10.7.3 SWOT Analysis
10.8 Chronix Biomedical
10.8.1 Company Overview
10.8.2 Role of Chronix Biomedical in the Liquid Biopsy Market
10.8.3 SWOT Analysis
10.9 Epic Sciences, Inc.
10.9.1 Company Overview
10.9.2 Role of Epic Sciences, Inc. in the Liquid Biopsy in the Market
10.9.3 SWOT Analysis
10.10 F. Hoffmann-La Roche AG
10.10.1 Company Overview
10.10.2 Role of F. Hoffmann-La Roche AG in the Liquid Biopsy Market
10.10.3 Financials
10.10.4 Key Insights about Financial Health of the company
10.10.5 Global Presence
10.10.6 SWOT Analysis
10.11 GUARDANT HEALTH, INC
10.11.1 Company Overview
10.11.2 Role of GUARDANT HEALTH, Inc. in Liquid Biopsy Market
10.11.3 SWOT Analysis
10.12 Illumina, Inc.
10.12.1 Company Overview
10.12.2 Role of Illumina, Inc. in the Liquid Biopsy Market
10.12.3 Financials
10.12.4 Key Insights about Financial Health of the Company
10.12.5 Global Presence
10.12.6 SWOT Analysis
10.13 MDxHealth, Inc.
10.13.1 Company Overview
10.13.2 Role of MDxHealth, Inc. in the Liquid Biopsy Market
10.13.3 Financials
10.13.4 Key Insights on the Financial Health of the Company
10.13.5 Global Presence
10.13.6 SWOT Analysis
10.14 Menarini Silicon Biosystems, Inc.
10.14.1 Company Overview
10.14.2 Role of Menarini Silicon Biosystems in the Liquid Biopsy Market
10.14.3 SWOT Analysis
10.15 Myriad Genetics, Inc.
10.15.1 Company Overview
10.15.2 Role of Myriad Genetics, Inc. in Liquid Biopsy Market
10.15.3 Financials
10.15.3.1 Key Insights of the Financial Health of the Company
10.15.4 Global Presence
10.15.5 SWOT Analysis
10.16 Natera, Inc.
10.16.1 Company Overview
10.16.2 Role of Natera, Inc. in the Liquid Biopsy Market
10.16.3 Financials
10.16.3.1 Key Insights of the Financial Health about the Company
10.16.4 Global Presence
10.16.5 SWOT Analysis
10.17 NeoGenomics Laboratories, Inc.
10.17.1 Company Overview
10.17.2 Role of NeoGenomics Laboratories, Inc. in the Liquid Biopsy Market
10.17.3 Financials
10.17.3.1 Key Insights on the Financial Health of the Company
10.17.4 Global Presence
10.17.5 SWOT Analysis
10.18 Personal Genome Diagnostics, Inc.
10.18.1 Company Overview
10.18.2 Role of Personal Genome Diagnostics, Inc. in Liquid Biopsy Market
10.18.3 SWOT Analysis
10.19 Qiagen N.V.
10.19.1 Company Overview
10.19.2 Role of Qiagen N.V. in the Liquid Biopsy Market
10.19.3 Financials
10.19.3.1 Key Insights on the Financial Health of the Company
10.19.4 Global Presence
10.19.5 SWOT Analysis
10.20 Resolution Bioscience, Inc.
10.20.1 Company Overview
10.20.2 Role of Resolution Biosciences, Inc. in the Liquid Biopsy Market
10.20.3 SWOT Analysis
10.21 Sysmex Corporation
10.21.1 Company Overview
10.21.2 Role of Sysmex Corporation in the Liquid Biopsy Market
10.21.3 Financials
10.21.4 Key Insights of the Financial Health of the Company
10.21.5 Global Presence
10.21.6 SWOT Analysis
10.22 Thermo Fisher Scientific
10.22.1 Company Overview
10.22.2 Role of Thermo Fisher Scientific in the Liquid Biopsy Market
10.22.3 Financials
10.22.3.1 Key Insights on the Financial Health of the Company
10.22.4 Global Presence
10.22.5 SWOT Analysis
11 RESEARCH SCOPE AND METHODOLOGY
11.1 Report Scope
11.2 Global Liquid Biopsy Market: Research Methodology
1 MARKET OVERVIEW
1.1 Historical Trends
1.2 Comparative Analysis of Tissue Biopsy and Liquid Biopsy
1.3 Clinical Applications of Liquid Biopsy
1.4 Trends for Liquid Biopsy
1.5 Assumptions and Limitations for Market Size Calculations
1.6 Global Liquid Biopsy Market Scenario
2 MARKET DYNAMICS
2.1 Impact Analysis
2.2 Market Drivers
2.2.1 Potential of Liquid Biopsy
2.2.2 Ability to Monitor Clonal Mutations
2.2.3 Growing Prominence of Precision Medicine
2.3 Market Restraints
2.3.1 Uncertain Reimbursement and Regulatory Policies
2.3.2 High Pricing Pressure
2.3.3 Adoption of Traditional Diagnosis Practices
2.4 Market Opportunities
2.4.1 Development of Medication Package Deals
2.4.2 Expansion into Emerging markets
2.4.3 Scope of Liquid Biopsy for Intervention: Diagnosis of Non-oncology Disorders
3 COMPETITIVE INSIGHTS
3.1 Key Strategies and Developments
3.1.1 Mergers and Acquisitions
3.1.2 Business Expansions
3.1.3 Awards, Recognitions, Certifications, and Others
3.1.4 Product Launches and Enhancements
3.1.5 Joint Ventures, Partnerships, and Collaborations
3.2 Market Share Analysis
3.3 Growth Share Analysis
3.3.1 Growth Share Analysis (by Prominent Companies)
3.3.2 Growth Share Analysis (by Therapeutic Application)
3.3.3 Growth Share Analysis (by Biomarker Type)
3.3.4 Growth Share Analysis (by Clinical Application)
3.4 Global Comprehensive Competitive Index (CCI)
3.5 Industry Attractiveness
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyer
3.5.3 Threat of New Entrants
3.5.4 Threat of Substitute Products
3.5.5 Intensity of Competitive Rivalry
4 INDUSTRY INSIGHTS
4.1 Introduction
4.2 Patent Analysis
4.3 Funding Scenario
4.4 Regulatory Bodies
4.5 Clinical Laboratory Improvement Amendments (CLIA) Program
4.6 Government Initiatives
5 GLOBAL LIQUID BIOPSY MARKET (BY CIRCULATING BIOMARKERS)
5.1 Circulating Tumor DNA (cTDNA)
5.2 Circulating Tumor Cells (CTCs)
5.3 Cell-Free DNA (cfDNA)
5.4 Extracellular Vesicles and Others
6 GLOBAL LIQUID BIOPSY MARKET (BY PRODUCTS)
6.1 Tests/Services
6.2 Kits and Consumables
6.3 Instruments
7 GLOBAL LIQUID BIOPSY MARKET (BY THERAPEUTIC APPLICATION)
7.1 Lung Cancer
7.2 Breast Cancer
7.3 Prostate Cancer
7.4 Colorectal Cancer
7.5 Melanoma Cancer
7.6 Other Types of Cancer
7.7 Non-Oncology Application
8 GLOBAL LIQUID BIOPSY MARKET (BY CLINICAL APPLICATIONS)
8.1 Treatment Monitoring
8.2 Prognosis and Reoccurrence Monitoring
8.3 Treatment Selection
8.4 Diagnosis and Screening
9 GLOBAL LIQUID BIOPSY MARKET (BY REGION)
9.1 Analysis of Growth Potential of Different Countries: Global Liquid Biopsy Market
9.1.1 Cluster-1: China and India
9.1.2 Cluster-2: The U.S. and Japan
9.1.3 Cluster-3: Brazil, South Korea, Spain, Italy, The U.K., France, and Canada
9.1.4 Cluster-4: Germany, Australia, Singapore, Mexico, and Saudi Arabia
9.2 North America
9.2.1 The U.S.
9.2.1.1 U.S. Liquid Biopsy Market (by Therapeutic Application)
9.2.2 Canada
9.2.2.1 Canada Liquid Biopsy Market (by Therapeutic Application)
9.3 Europe
9.3.1 Germany
9.3.1.1 Germany Liquid Biopsy Market (by Therapeutic Application)
9.3.2 France
9.3.2.1 France Liquid Biopsy Market (by Therapeutic Application)
9.3.3 The U.K.
9.3.3.1 U.K. Liquid Biopsy Market (by Therapeutic Application)
9.3.4 Italy
9.3.4.1 Italy Liquid Biopsy Market (by Therapeutic Application)
9.3.5 Spain
9.3.5.1 Spain Liquid Biopsy Market (by Therapeutic Application)
9.3.6 Rest-of-Europe
9.4 Asia-Pacific
9.4.1 China
9.4.1.1 China Liquid Biopsy Market (by Therapeutic Application)
9.4.2 Japan
9.4.2.1 Japan Liquid Biopsy Market (by Therapeutic Application)
9.4.3 India
9.4.3.1 India Liquid Biopsy Market (by Therapeutic Application)
9.4.4 Australia
9.4.4.1 Australia Liquid Biopsy Market (by Therapeutic Application)
9.4.5 South Korea
9.4.5.1 South Korea Liquid Biopsy Market (by Therapeutic Application)
9.4.6 Singapore
9.4.6.1 Singapore Liquid Biopsy Market (by Therapeutic Application)
9.4.7 Rest-of-Asia-Pacific
9.5 Latin America and Middle East
9.5.1 Brazil
9.5.1.1 Brazil Liquid Biopsy Market (by Therapeutic Application)
9.5.2 Mexico
9.5.2.1 Mexico Liquid Biopsy Market (by Therapeutic Application)
9.5.3 Saudi Arabia
9.5.3.1 Saudi Arabia Liquid Biopsy Market (by Therapeutic Application)
9.5.4 Rest-of-Latin America and Middle East
9.6 Rest-of-the-World
10 COMPANY PROFILES
10.1 Overview
10.2 Abcodia Ltd.
10.2.1 Company Overview
10.2.2 Role of Abcodia Ltd. in the Liquid Biopsy Market
10.2.3 SWOT Analysis
10.3 Adaptive Biotechnologies
10.3.1 Company Overview
10.3.2 Role of Adaptive Biotechnologies Corporation in the Liquid Biopsy Market
10.3.3 SWOT Analysis
10.4 ANGLE plc
10.4.1 Company Overview
10.4.2 Role of ANGLE plc in the Liquid Biopsy Market
10.4.3 Financials
10.4.3.1 Key Insights on the Financial Health of the Company
10.4.4 Global Presence
10.4.5 SWOT Analysis
10.5 Biocept, Inc.
10.5.1 Company Overview
10.5.2 Role of Biocept, Inc. in Liquid Biopsy Market
10.5.3 Financials
10.5.4 Key Insights about Financial Health of the Company
10.5.5 SWOT Analysis
10.6 Bio-Rad Laboratories, Inc.
10.6.1 Company Overview
10.6.2 Role of Bio-Rad Laboratories, Inc. in Liquid Biopsy Market
10.6.3 Financials
10.6.4 Key Insights about Financial Health of the company
10.6.5 Global Presence
10.6.6 SWOT Analysis
10.7 Cynvenio Biosystems, Inc.
10.7.1 Company Overview
10.7.2 Role of Cynvenio Biosystems, Inc. in the Liquid Biopsy Market
10.7.3 SWOT Analysis
10.8 Chronix Biomedical
10.8.1 Company Overview
10.8.2 Role of Chronix Biomedical in the Liquid Biopsy Market
10.8.3 SWOT Analysis
10.9 Epic Sciences, Inc.
10.9.1 Company Overview
10.9.2 Role of Epic Sciences, Inc. in the Liquid Biopsy in the Market
10.9.3 SWOT Analysis
10.10 F. Hoffmann-La Roche AG
10.10.1 Company Overview
10.10.2 Role of F. Hoffmann-La Roche AG in the Liquid Biopsy Market
10.10.3 Financials
10.10.4 Key Insights about Financial Health of the company
10.10.5 Global Presence
10.10.6 SWOT Analysis
10.11 GUARDANT HEALTH, INC
10.11.1 Company Overview
10.11.2 Role of GUARDANT HEALTH, Inc. in Liquid Biopsy Market
10.11.3 SWOT Analysis
10.12 Illumina, Inc.
10.12.1 Company Overview
10.12.2 Role of Illumina, Inc. in the Liquid Biopsy Market
10.12.3 Financials
10.12.4 Key Insights about Financial Health of the Company
10.12.5 Global Presence
10.12.6 SWOT Analysis
10.13 MDxHealth, Inc.
10.13.1 Company Overview
10.13.2 Role of MDxHealth, Inc. in the Liquid Biopsy Market
10.13.3 Financials
10.13.4 Key Insights on the Financial Health of the Company
10.13.5 Global Presence
10.13.6 SWOT Analysis
10.14 Menarini Silicon Biosystems, Inc.
10.14.1 Company Overview
10.14.2 Role of Menarini Silicon Biosystems in the Liquid Biopsy Market
10.14.3 SWOT Analysis
10.15 Myriad Genetics, Inc.
10.15.1 Company Overview
10.15.2 Role of Myriad Genetics, Inc. in Liquid Biopsy Market
10.15.3 Financials
10.15.3.1 Key Insights of the Financial Health of the Company
10.15.4 Global Presence
10.15.5 SWOT Analysis
10.16 Natera, Inc.
10.16.1 Company Overview
10.16.2 Role of Natera, Inc. in the Liquid Biopsy Market
10.16.3 Financials
10.16.3.1 Key Insights of the Financial Health about the Company
10.16.4 Global Presence
10.16.5 SWOT Analysis
10.17 NeoGenomics Laboratories, Inc.
10.17.1 Company Overview
10.17.2 Role of NeoGenomics Laboratories, Inc. in the Liquid Biopsy Market
10.17.3 Financials
10.17.3.1 Key Insights on the Financial Health of the Company
10.17.4 Global Presence
10.17.5 SWOT Analysis
10.18 Personal Genome Diagnostics, Inc.
10.18.1 Company Overview
10.18.2 Role of Personal Genome Diagnostics, Inc. in Liquid Biopsy Market
10.18.3 SWOT Analysis
10.19 Qiagen N.V.
10.19.1 Company Overview
10.19.2 Role of Qiagen N.V. in the Liquid Biopsy Market
10.19.3 Financials
10.19.3.1 Key Insights on the Financial Health of the Company
10.19.4 Global Presence
10.19.5 SWOT Analysis
10.20 Resolution Bioscience, Inc.
10.20.1 Company Overview
10.20.2 Role of Resolution Biosciences, Inc. in the Liquid Biopsy Market
10.20.3 SWOT Analysis
10.21 Sysmex Corporation
10.21.1 Company Overview
10.21.2 Role of Sysmex Corporation in the Liquid Biopsy Market
10.21.3 Financials
10.21.4 Key Insights of the Financial Health of the Company
10.21.5 Global Presence
10.21.6 SWOT Analysis
10.22 Thermo Fisher Scientific
10.22.1 Company Overview
10.22.2 Role of Thermo Fisher Scientific in the Liquid Biopsy Market
10.22.3 Financials
10.22.3.1 Key Insights on the Financial Health of the Company
10.22.4 Global Presence
10.22.5 SWOT Analysis
11 RESEARCH SCOPE AND METHODOLOGY
11.1 Report Scope
11.2 Global Liquid Biopsy Market: Research Methodology
LIST OF TABLES
Table 1 Cancer Incidences (by Region), 2015
Table 1.1 Tissue Biopsy vs. Liquid Biopsy
Table 2.1 Impact Analysis
Table 2.2 Governmental Initiatives for the Market Growth of Precision Medicine
Table 2.3 Incidence of Leading Cancer Types (by Region), 2015
Table 4.1 List of Regulatory Bodies across the World
Table 4.2 List of Regulatory Authorities involved in CLIA Program
Table 4.3 Government Initiatives
Table 7.1 Lung Cancer Incidence in Top Countries, 2012-2030
Table 7.2 Breast Cancer Incidence in Top Countries, 2012-2030
Table 7.3 Prostate Cancer Incidence in Top Countries, 2012-2030
Table 7.4 Colorectal Cancer Incidence in Top Countries, 2012-2030
Table 7.5 Estimated Incidence and Mortality of Melanoma Worldwide in 2012
Table 7.6 Melanoma Cancer Incidence in Top Countries, 2012-2030
Table 7.7 Ovarian Cancer Incidence in Top Countries, 2012-2030
Table 7.8 Stomach Cancer Incidence in Top Countries, 2012-2030
Table 9.1 Analysis of Growth Potential (by Countries)
Table 9.2 Prevalence of Different Types of Cancer (by Country), 2017
Table 9.3 Prevalence of Different Types of Cancer (by Country), 2017
Table 9.4 The U.S: Prevalence of Different Types of Cancer, 2015-2030
Table 9.5 Canada: Prevalence of Different Types of Cancer, 2015-2030
Table 9.6 Germany: Prevalence of Different Types of Cancer, 2015-2030
Table 9.7 France: Prevalence of Different Types of Cancer, 2015-2030
Table 9.8 The U.K.: Prevalence of Different Types of Cancer, 2015-2030
Table 9.9 Italy: Prevalence of Different Types of Cancer, 2015-2030
Table 9.10 Spain: Prevalence of Different Types of Cancer, 2015-2030
Table 9.11 China: Prevalence of Different Types of Cancer, 2015-2030
Table 9.12 Japan: Prevalence of Different Types of Cancer, 2015-2030
Table 9.13 India: Prevalence of Different Types of Cancer, 2015-2030
Table 9.14 Australia: Prevalence of Different Types of Cancer, 2015-2030
Table 9.15 South Korea: Prevalence of Different Types of Cancer, 2015-2030
Table 9.16 Singapore: Prevalence of Different Types of Cancer, 2015-2030
Table 9.17 Brazil: Prevalence of Different Types of Cancer, 2015-2030
Table 9.18 Mexico: Prevalence of Different Types of Cancer, 2015-2030
Table 9.19 Saudi Arabia: Prevalence of Different Types of Cancer, 2015-2030
Table 1 Cancer Incidences (by Region), 2015
Table 1.1 Tissue Biopsy vs. Liquid Biopsy
Table 2.1 Impact Analysis
Table 2.2 Governmental Initiatives for the Market Growth of Precision Medicine
Table 2.3 Incidence of Leading Cancer Types (by Region), 2015
Table 4.1 List of Regulatory Bodies across the World
Table 4.2 List of Regulatory Authorities involved in CLIA Program
Table 4.3 Government Initiatives
Table 7.1 Lung Cancer Incidence in Top Countries, 2012-2030
Table 7.2 Breast Cancer Incidence in Top Countries, 2012-2030
Table 7.3 Prostate Cancer Incidence in Top Countries, 2012-2030
Table 7.4 Colorectal Cancer Incidence in Top Countries, 2012-2030
Table 7.5 Estimated Incidence and Mortality of Melanoma Worldwide in 2012
Table 7.6 Melanoma Cancer Incidence in Top Countries, 2012-2030
Table 7.7 Ovarian Cancer Incidence in Top Countries, 2012-2030
Table 7.8 Stomach Cancer Incidence in Top Countries, 2012-2030
Table 9.1 Analysis of Growth Potential (by Countries)
Table 9.2 Prevalence of Different Types of Cancer (by Country), 2017
Table 9.3 Prevalence of Different Types of Cancer (by Country), 2017
Table 9.4 The U.S: Prevalence of Different Types of Cancer, 2015-2030
Table 9.5 Canada: Prevalence of Different Types of Cancer, 2015-2030
Table 9.6 Germany: Prevalence of Different Types of Cancer, 2015-2030
Table 9.7 France: Prevalence of Different Types of Cancer, 2015-2030
Table 9.8 The U.K.: Prevalence of Different Types of Cancer, 2015-2030
Table 9.9 Italy: Prevalence of Different Types of Cancer, 2015-2030
Table 9.10 Spain: Prevalence of Different Types of Cancer, 2015-2030
Table 9.11 China: Prevalence of Different Types of Cancer, 2015-2030
Table 9.12 Japan: Prevalence of Different Types of Cancer, 2015-2030
Table 9.13 India: Prevalence of Different Types of Cancer, 2015-2030
Table 9.14 Australia: Prevalence of Different Types of Cancer, 2015-2030
Table 9.15 South Korea: Prevalence of Different Types of Cancer, 2015-2030
Table 9.16 Singapore: Prevalence of Different Types of Cancer, 2015-2030
Table 9.17 Brazil: Prevalence of Different Types of Cancer, 2015-2030
Table 9.18 Mexico: Prevalence of Different Types of Cancer, 2015-2030
Table 9.19 Saudi Arabia: Prevalence of Different Types of Cancer, 2015-2030
LIST OF FIGURES
Figure 1 Few Citations of Liquid Biopsy
Figure 2 Facts about Cancer
Figure 3 Market Drivers and Market Restraints
Figure 4 Market Statistics
Figure 5 Global Liquid Biopsy Market, 2017-2028
Figure 6 Global Liquid Biopsy Market (by Products), 2017 and 2028
Figure 7 Global Liquid Biopsy Market (by Circulating Biomarker), 2017-2028
Figure 8 Global Liquid Biopsy Market (by Clinical Application), 2017-2028
Figure 9 Global Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 10 Global Liquid Biopsy Market (by Region), 2017-2028
Figure 11 Adoption Rate: Tissue Biopsy vs. Liquid biopsy
Figure 1.1 Different Types of Biomarkers in Liquid Biopsy
Figure 1.2 Evolution of Liquid Biopsy with Progress in Molecular Technologies and Biomarker Discovery
Figure 1.3 Workflow Model of Tissue and Liquid Biopsy
Figure 1.4 Clinical Applications of Liquid Biopsy
Figure 1.5 Global Liquid Biopsy Market, 2017-2028
Figure 2.1 Market Dynamics of Global Liquid Biopsy Market
Figure 3.1 Competitive Landscape, January 2015-July 2018
Figure 3.2 Share of Key Developments and Strategies, January 2015-July 2018
Figure 3.3 Mergers and Acquisitions Share (by Companies), January 2015-July 2018
Figure 3.4 Business Expansions Share (by Companies), January 2015-July 2018
Figure 3.5 Awards, Recognitions, Certifications and Others Share (by Companies), January 2015-July 2018
Figure 3.6 Product Launches Share (by Companies), January 2015-July 2018
Figure 3.7 Joint Ventures, Partnerships, and Collaborations Share (by Companies), January 2015-July 2018
Figure 3.8 Market Share Analysis: Global Liquid Biopsy Market, 2016 and 2017
Figure 3.9 Growth Share Matrix for Global Liquid Biopsy Market (by Prominent Companies), 2018-2020
Figure 3.10 Growth Share Matrix for Global Liquid Biopsy Market (by Therapeutic Application), 2017
Figure 3.11 Growth Share Matrix for Global Liquid Biopsy Market (by Biomarker Type), 2017
Figure 3.12 Growth Share Matrix for Global Liquid Biopsy Market (by Clinical Application), 2017
Figure 3.13 Global Comprehensive Competitive Index (by Market Leaders), 2017
Figure 3.14 Porter’s Five Forces Analysis
Figure 3.15 Bargaining Power of Suppliers: Overall Impact, 2014-2028
Figure 3.16 Bargaining Power of Buyers: Overall Impact, 2014-2028
Figure 3.17 Threat of New Entrant: Overall Impact, 2014-2028
Figure 3.18 Threat of Substitute Products: Overall Impact, 2014-2028
Figure 3.19 Intensity of Competitive Rivalry: Overall Impact, 2014-2028
Figure 4.1 Industry Insights, January 2015-May 2018
Figure 4.2 Patent Share (by Assignee), January 2015-July 2018
Figure 4.3 Research Investments by Companies, $Million, January 2015-Decemeber 2017
Figure 4.4 Categorization of Test Methods (by FDA)
Figure 5.1 Different Circulating Biomarkers
Figure 5.2 Global Liquid Biopsy Market (by Circulating Biomarker), 2017 and 2028
Figure 5.3 Global Liquid Biopsy Market (by cTDNA), 2017-2028
Figure 5.4 CTCs vs. cTDNA Analysis
Figure 5.5 Global Liquid Biopsy Market (by CTCs), 2017-2028
Figure 5.6 Global Liquid Biopsy Market (by cfDNA), 2017-2028
Figure 5.7 Global Liquid Biopsy Market (by Extracellular Vesicles and Others), 2017-2028
Figure 6.1 Global Liquid Biopsy Market (by Products)
Figure 6.2 Global Liquid Biopsy Market (by Products), 2017-2028
Figure 6.3 Global Liquid Biopsy Market (by Tests/Services), 2017-2028
Figure 6.4 Global Liquid Biopsy Market (by Kits and Consumables), 2017-2028
Figure 6.5 Global Liquid Biopsy Market (by Instruments), 2017-2028
Figure 7.1 Global Liquid Biopsy Market (by Therapeutic Application)
Figure 7.2 Global Liquid Biopsy Market (by Therapeutic Applications), 2017-2028
Figure 7.3 Types of Lung Cancer
Figure 7.4 Global Liquid Biopsy Market (by Lung Cancer), 2017-2028
Figure 7.5 Types of Breast Cancer
Figure 7.6 Global Liquid Biopsy Market (by Breast Cancer), 2017-2028
Figure 7.7 Global Liquid Biopsy Market (by Prostate Cancer), 2017-2028
Figure 7.8 Global Liquid Biopsy Market (by Colorectal Cancer), 2017-2028
Figure 7.9 Global Liquid Biopsy Market (by Melanoma Cancer), 2017-2028
Figure 7.10 Global Liquid Biopsy Market (by Other Types of Cancer), 2017-2028
Figure 7.11 Global Liquid Biopsy Market (by Non-Oncology Applications), 2017-2028
Figure 8.1 Global Liquid Biopsy Market (by Clinical Applications)
Figure 8.2 Global Liquid Biopsy Market (by Clinical Applications), 2017-2028
Figure 8.3 Global Liquid Biopsy Market (by Treatment Monitoring), 2017-2028
Figure 8.4 Global Liquid Biopsy Market (by Prognosis and Reoccurrence Monitoring), 2017-2028
Figure 8.5 Global Liquid Biopsy Market (by Treatment Selection), 2017-2028
Figure 8.6 Global Liquid Biopsy Market (by Diagnosis and Screening), 2017-2028
Figure 9.1 Global Liquid Biopsy Market Scenario, 2017 and 2028
Figure 9.2 Global Liquid Biopsy Market (by Region), 2017-2028
Figure 9.3 Global Liquid Biopsy Market Share (by Region), 2017 and 2028
Figure 9.4 Cluster Analysis: Global Liquid Biopsy Market
Figure 9.5 Compound Annual Growth Rate of Liquid Biopsy Market (by Country), 2018-2028
Figure 9.6 Compound Annual Growth Rate of Liquid Biopsy Market (by Country), 2018-2028
Figure 9.7 Compound Annual Growth Rate of Liquid Biopsy Market (by Country), 2018-2028
Figure 9.8 Compound Annual Growth Rate of Liquid Biopsy Market (by Country), 2018-2028
Figure 9.9 North America: Liquid Biopsy Market, (2017-2028)
Figure 9.10 North America: Market Dynamics
Figure 9.11 North America: Liquid biopsy Market (by Country), 2017-2028
Figure 9.12 The U.S: Liquid Biopsy Market, 2017-2028
Figure 9.13 The U.S: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.14 Canada: Liquid Biopsy Market, 2017-2028
Figure 9.15 Canada: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.16 Europe: Liquid Biopsy Market, 2017-2028
Figure 9.17 Europe: Market Dynamics
Figure 9.18 Europe: Liquid Biopsy Market (by Country), 2017-2028
Figure 9.19 Germany: Liquid Biopsy Market, 2017-2028
Figure 9.20 Germany: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.21 France: Liquid Biopsy Market, 2017-2028
Figure 9.22 France: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.23 The U.K.: Liquid Biopsy Market, 2017-2028
Figure 9.24 The U.K.: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.25 Italy: Liquid Biopsy Market, 2017-2028
Figure 9.26 Italy: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.27 Spain: Liquid Biopsy Market, 2017-2028
Figure 9.28 Spain: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.29 Rest-of-Europe: Liquid Biopsy Market, 2017-2028
Figure 9.30 Asia-Pacific: Liquid Biopsy Market, 2017-2028
Figure 9.31 Asia-Pacific: Market Dynamics
Figure 9.32 Asia Pacific: Liquid Biopsy Market (by Country), 2017-2028
Figure 9.33 China: Liquid Biopsy Market, 2017-2028
Figure 9.34 China: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.35 Japan: Liquid Biopsy Market, 2017-2028
Figure 9.36 Japan: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.37 India: Liquid Biopsy Market, 2017-2028
Figure 9.38 India: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.39 Australia: Liquid Biopsy Market, 2017-2028
Figure 9.40 Australia: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.41 South Korea: Liquid Biopsy Market, 2017-2028
Figure 9.42 South Korea: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.43 Singapore: Liquid Biopsy Market, 2017-2028
Figure 9.44 Singapore: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.45 Rest-of-Asia Pacific: Liquid Biopsy Market, 2017-2028
Figure 9.46 Latin America: Liquid Biopsy Market, 2017-2028
Figure 9.47 Latin America: Market Dynamics
Figure 9.48 Latin America: Liquid Biopsy Market (by Country), 2017-2028
Figure 9.49 Brazil: Liquid Biopsy Market, 2017-2028
Figure 9.50 Brazil: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.51 Mexico: Liquid Biopsy Market, 2017-2028
Figure 9.52 Mexico: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.53 Saudi Arabia: Liquid Biopsy Market, 2017-2028
Figure 9.54 Saudi Arabia: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.55 Rest-of-Latin America and Middle East: Liquid Biopsy Market, 2017-2028
Figure 9.56 Rest-of-the-World: Liquid Biopsy Market, 2017-2028
Figure 10.1 Shares of Key Company Profiles
Figure 10.2 Abcodia Ltd.: Product Offerings for Global Liquid Biopsy Market
Figure 10.3 Abcodia Ltd.: SWOT Analysis
Figure 10.4 Adaptive Biotechnologies: Product Offerings for Global Liquid Biopsy Market
Figure 10.5 Adaptive Biotechnologies: SWOT Analysis
Figure 10.6 ANGLE plc: Product Offerings for Global Liquid Biopsy Market
Figure 10.7 ANGLE plc: Overall Financials, 2015-2017
Figure 10.8 ANGLE plc: Revenue (by Region), 2016 and 2017
Figure 10.9 ANGLE plc: R&D Expense, 2015-2017
Figure 10.10 ANGLE plc: Revenue Forecast, 2015-2020
Figure 10.11 ANGLE plc: Global Presence
Figure 10.12 ANGLE plc: SWOT Analysis
Figure 10.13 Biocept, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.14 Biocept, Inc.: Overall Financials, 2015-2017
Figure 10.15 Biocept, Inc.: R&D Expense, 2015-2017
Figure 10.16 Biocept, Inc.: Revenue Forecast, 2015-2020
Figure 10.17 Biocept, Inc.: SWOT Analysis
Figure 10.18 Bio-Rad Laboratories, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.19 Bio-Rad laboratories, Inc.: Overall Financials, 2015-2017
Figure 10.20 Bio-Rad Laboratories, Inc.: Revenue (by Business Segment), 2015-2017
Figure 10.21 Bio-Rad Laboratories, Inc.: Revenue (by Region), 2015-2017
Figure 10.22 Bio-Rad Laboratories, Inc.: R&D Expense, 2015-2017
Figure 10.23 Bio-Rad Laboratories, Inc.: Revenue Forecast, 2015-2020
Figure 10.24 Bio-Rad Laboratories, Inc.: Global Presence
Figure 10.25 Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 10.26 Cynvenio Biosystems, Inc.: Overall Product Portfolio
Figure 10.27 Cynvenio Biosystems, Inc.: SWOT Analysis
Figure 10.28 Chronix Biomedical: Product Offerings for Global Liquid Biopsy Market
Figure 10.29 Chronix Biomedical: SWOT Analysis
Figure 10.30 Epic Sciences, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.31 Epic Sciences, Inc.: SWOT Analysis
Figure 10.32 F. Hoffmann-La Roche AG: Product Offerings for Global Liquid Biopsy Market
Figure 10.33 F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
Figure 10.34 F. Hoffmann-La Roche AG: Revenue (by Business Segment), 2015-2017
Figure 10.35 F. Hoffmann-La Roche Ltd.: Revenue (by Diagnostics Sub-division), 2015-2017
Figure 10.36 F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017
Figure 10.37 F. Hoffmann-La Roche AG: R&D Expense, 2015-2017
Figure 10.38 F. Hoffmann-La Roche AG: Revenue Forecast, 2015-2020
Figure 10.39 F. Hoffmann-La Roche AG: Global Presence
Figure 10.40 F. Hoffmann-La Roche AG: SWOT Analysis
Figure 10.41 GUARDANT HEALTH, INC.: Product Offerings for Global Liquid Biopsy Market
Figure 10.42 GUARDANT HEALTH, INC.: SWOT Analysis
Figure 10.43 Illumina, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.44 Illumina, Inc.: Overall Financials, 2015-2017
Figure 10.45 Illumina, Inc.: Revenue (by Business Segment), 2015-2017
Figure 10.46 Illumina, Inc.: Revenue (by Region), 2015-2017
Figure 10.47 Illumina, Inc.: R&D Expense, 2015-2017
Figure 10.48 Illumina, Inc.: Revenue Forecast, 2015-2020
Figure 10.49 Illumina, Inc.: Global Presence
Figure 10.50 Illumina, Inc.: SWOT Analysis
Figure 10.51 MDxHealth, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.52 MDxHealth, Inc.: Overall Financials, 2015-2017
Figure 10.53 MDxHealth, Inc.: R&D Expanse, 2015-2017
Figure 10.54 MDxHealth, Inc.: Revenue Forecast, 2015-2017
Figure 10.55 MDxHealth, Inc.: Global Presence
Figure 10.56 MDxHealth, Inc.: SWOT Analysis
Figure 10.57 Menarini Silicon Biosystems, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.58 Menarini Silicon Biosystems, Inc.: SWOT Analysis
Figure 10.59 Myriad Genetics, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.60 Myriad Genetics, Inc.: Overall Financials, 2015-2017
Figure 10.61 Myriad Genetics, Inc.: Revenue (by Business Segment), 2015-2017
Figure 10.62 Myriad Genetics, Inc.: Revenue (by Region), 2015-2017
Figure 10.63 Myriad Genetics, Inc.: R&D Expense, 2015-2017
Figure 10.64 Myriad Genetics, Inc.: Revenue Forecast, 2015-2020
Figure 10.65 Myriad Genetics, Inc.: Global Presence
Figure 10.66 Myriad Genetics, Inc.: SWOT Analysis
Figure 10.67 Natera, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.68 Natera, Inc.: Overall Financials, 2015-2017
Figure 10.69 Natera, Inc.: Revenue (by Region), 2015-2017
Figure 10.70 Natera, Inc.: R&D Expense, 2015-2017
Figure 10.71 Natera, Inc.: Revenue Forecast, 2015-2020
Figure 10.72 Natera, Inc.: Global Presence
Figure 10.73 Natera, Inc.: SWOT Analysis
Figure 10.74 NeoGenomics Laboratories, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.75 NeoGenomics Laboratories, Inc.: Overall Financials, 2015-2017
Figure 10.76 NeoGenomics Laboratories, Inc.: Revenue (by Business Segment), 2015-2017
Figure 10.77 NeoGenomics Laboratories, Inc.: R&D Expense, 2015-2017
Figure 10.78 NeoGenomics Laboratories, Inc.: Revenue Forecast, 2015-2020
Figure 10.79 NeoGenomics Laboratories, Inc.: Global Presence
Figure 10.80 NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 10.81 Personal Genome Diagnostics, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.82 Personal Genome Diagnostics, Inc.: SWOT Analysis
Figure 10.83 Qiagen N.V.: Product Offerings for Global Liquid Biopsy Market
Figure 10.84 Qiagen N.V.: Overall Financials, 2015-2017
Figure 10.85 Qiagen N.V.: Revenue (by Business Segment), 2015-2017
Figure 10.86 Qiagen N.V.: Revenue (by Region), 2015-2017
Figure 10.87 Qiagen N.V.: R&D Expense, 2015-2017
Figure 10.88 Qiagen N.V.: Revenue Forecast, 2015-2020
Figure 10.89 Qiagen N.V.: Global Presence
Figure 10.90 Qiagen N.V.: SWOT Analysis
Figure 10.91 Resolution Bioscience, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.92 Resolution Bioscience, Inc.: SWOT Analysis
Figure 10.93 Sysmex Corporation: Product Offerings for Global Liquid Biopsy Market
Figure 10.94 Sysmex Corporation: Overall Financials, 2015-2017
Figure 10.95 Sysmex Corporation: Revenue (by Business Segment), 2016 and 2017
Figure 10.96 Sysmex Corporation: Revenue (by Business Segment), 2015
Figure 10.97 Sysmex Corporation: Revenue by Product Type (2015-2017)
Figure 10.98 Sysmex Corporation: Revenue (by Region), 2015-2017
Figure 10.99 Sysmex Corporation: R&D Expense, 2015-2017
Figure 10.100 Sysmex Corporation: Revenue Forecast, 2015-2020
Figure 10.101 Sysmex Corporation: Global Presence
Figure 10.102 Sysmex Corporation: SWOT Analysis
Figure 10.103 Thermo Fisher Scientific Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.104 Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017
Figure 10.105 Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2015-2017
Figure 10.106 Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017
Figure 10.107 Thermo Fisher Scientific Inc.: R&D Expense, 2015-2017
Figure 10.108 Thermo Fisher Scientific Inc.: Revenue Forecast, 2015-2020
Figure 10.109 Thermo Fisher Scientific Inc.: Global Presence
Figure 10.110 Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 11.1 Global Liquid Biopsy: Market Segmentation
Figure 11.2 Global Liquid Biopsy Market Segmentation
Figure 11.3 Primary Research
Figure 11.4 Secondary Research
Figure 11.5 Data Triangulation
Figure 11.6 Top-down Approach (Segment-wise Analysis)
Figure 11.7 Bottom-up Approach (Segment-wise Analysis)
Figure 11.8 Assumptions and Limitations
Figure 11.9 Considered Factors for Data Prediction and Modelling
Figure 1 Few Citations of Liquid Biopsy
Figure 2 Facts about Cancer
Figure 3 Market Drivers and Market Restraints
Figure 4 Market Statistics
Figure 5 Global Liquid Biopsy Market, 2017-2028
Figure 6 Global Liquid Biopsy Market (by Products), 2017 and 2028
Figure 7 Global Liquid Biopsy Market (by Circulating Biomarker), 2017-2028
Figure 8 Global Liquid Biopsy Market (by Clinical Application), 2017-2028
Figure 9 Global Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 10 Global Liquid Biopsy Market (by Region), 2017-2028
Figure 11 Adoption Rate: Tissue Biopsy vs. Liquid biopsy
Figure 1.1 Different Types of Biomarkers in Liquid Biopsy
Figure 1.2 Evolution of Liquid Biopsy with Progress in Molecular Technologies and Biomarker Discovery
Figure 1.3 Workflow Model of Tissue and Liquid Biopsy
Figure 1.4 Clinical Applications of Liquid Biopsy
Figure 1.5 Global Liquid Biopsy Market, 2017-2028
Figure 2.1 Market Dynamics of Global Liquid Biopsy Market
Figure 3.1 Competitive Landscape, January 2015-July 2018
Figure 3.2 Share of Key Developments and Strategies, January 2015-July 2018
Figure 3.3 Mergers and Acquisitions Share (by Companies), January 2015-July 2018
Figure 3.4 Business Expansions Share (by Companies), January 2015-July 2018
Figure 3.5 Awards, Recognitions, Certifications and Others Share (by Companies), January 2015-July 2018
Figure 3.6 Product Launches Share (by Companies), January 2015-July 2018
Figure 3.7 Joint Ventures, Partnerships, and Collaborations Share (by Companies), January 2015-July 2018
Figure 3.8 Market Share Analysis: Global Liquid Biopsy Market, 2016 and 2017
Figure 3.9 Growth Share Matrix for Global Liquid Biopsy Market (by Prominent Companies), 2018-2020
Figure 3.10 Growth Share Matrix for Global Liquid Biopsy Market (by Therapeutic Application), 2017
Figure 3.11 Growth Share Matrix for Global Liquid Biopsy Market (by Biomarker Type), 2017
Figure 3.12 Growth Share Matrix for Global Liquid Biopsy Market (by Clinical Application), 2017
Figure 3.13 Global Comprehensive Competitive Index (by Market Leaders), 2017
Figure 3.14 Porter’s Five Forces Analysis
Figure 3.15 Bargaining Power of Suppliers: Overall Impact, 2014-2028
Figure 3.16 Bargaining Power of Buyers: Overall Impact, 2014-2028
Figure 3.17 Threat of New Entrant: Overall Impact, 2014-2028
Figure 3.18 Threat of Substitute Products: Overall Impact, 2014-2028
Figure 3.19 Intensity of Competitive Rivalry: Overall Impact, 2014-2028
Figure 4.1 Industry Insights, January 2015-May 2018
Figure 4.2 Patent Share (by Assignee), January 2015-July 2018
Figure 4.3 Research Investments by Companies, $Million, January 2015-Decemeber 2017
Figure 4.4 Categorization of Test Methods (by FDA)
Figure 5.1 Different Circulating Biomarkers
Figure 5.2 Global Liquid Biopsy Market (by Circulating Biomarker), 2017 and 2028
Figure 5.3 Global Liquid Biopsy Market (by cTDNA), 2017-2028
Figure 5.4 CTCs vs. cTDNA Analysis
Figure 5.5 Global Liquid Biopsy Market (by CTCs), 2017-2028
Figure 5.6 Global Liquid Biopsy Market (by cfDNA), 2017-2028
Figure 5.7 Global Liquid Biopsy Market (by Extracellular Vesicles and Others), 2017-2028
Figure 6.1 Global Liquid Biopsy Market (by Products)
Figure 6.2 Global Liquid Biopsy Market (by Products), 2017-2028
Figure 6.3 Global Liquid Biopsy Market (by Tests/Services), 2017-2028
Figure 6.4 Global Liquid Biopsy Market (by Kits and Consumables), 2017-2028
Figure 6.5 Global Liquid Biopsy Market (by Instruments), 2017-2028
Figure 7.1 Global Liquid Biopsy Market (by Therapeutic Application)
Figure 7.2 Global Liquid Biopsy Market (by Therapeutic Applications), 2017-2028
Figure 7.3 Types of Lung Cancer
Figure 7.4 Global Liquid Biopsy Market (by Lung Cancer), 2017-2028
Figure 7.5 Types of Breast Cancer
Figure 7.6 Global Liquid Biopsy Market (by Breast Cancer), 2017-2028
Figure 7.7 Global Liquid Biopsy Market (by Prostate Cancer), 2017-2028
Figure 7.8 Global Liquid Biopsy Market (by Colorectal Cancer), 2017-2028
Figure 7.9 Global Liquid Biopsy Market (by Melanoma Cancer), 2017-2028
Figure 7.10 Global Liquid Biopsy Market (by Other Types of Cancer), 2017-2028
Figure 7.11 Global Liquid Biopsy Market (by Non-Oncology Applications), 2017-2028
Figure 8.1 Global Liquid Biopsy Market (by Clinical Applications)
Figure 8.2 Global Liquid Biopsy Market (by Clinical Applications), 2017-2028
Figure 8.3 Global Liquid Biopsy Market (by Treatment Monitoring), 2017-2028
Figure 8.4 Global Liquid Biopsy Market (by Prognosis and Reoccurrence Monitoring), 2017-2028
Figure 8.5 Global Liquid Biopsy Market (by Treatment Selection), 2017-2028
Figure 8.6 Global Liquid Biopsy Market (by Diagnosis and Screening), 2017-2028
Figure 9.1 Global Liquid Biopsy Market Scenario, 2017 and 2028
Figure 9.2 Global Liquid Biopsy Market (by Region), 2017-2028
Figure 9.3 Global Liquid Biopsy Market Share (by Region), 2017 and 2028
Figure 9.4 Cluster Analysis: Global Liquid Biopsy Market
Figure 9.5 Compound Annual Growth Rate of Liquid Biopsy Market (by Country), 2018-2028
Figure 9.6 Compound Annual Growth Rate of Liquid Biopsy Market (by Country), 2018-2028
Figure 9.7 Compound Annual Growth Rate of Liquid Biopsy Market (by Country), 2018-2028
Figure 9.8 Compound Annual Growth Rate of Liquid Biopsy Market (by Country), 2018-2028
Figure 9.9 North America: Liquid Biopsy Market, (2017-2028)
Figure 9.10 North America: Market Dynamics
Figure 9.11 North America: Liquid biopsy Market (by Country), 2017-2028
Figure 9.12 The U.S: Liquid Biopsy Market, 2017-2028
Figure 9.13 The U.S: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.14 Canada: Liquid Biopsy Market, 2017-2028
Figure 9.15 Canada: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.16 Europe: Liquid Biopsy Market, 2017-2028
Figure 9.17 Europe: Market Dynamics
Figure 9.18 Europe: Liquid Biopsy Market (by Country), 2017-2028
Figure 9.19 Germany: Liquid Biopsy Market, 2017-2028
Figure 9.20 Germany: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.21 France: Liquid Biopsy Market, 2017-2028
Figure 9.22 France: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.23 The U.K.: Liquid Biopsy Market, 2017-2028
Figure 9.24 The U.K.: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.25 Italy: Liquid Biopsy Market, 2017-2028
Figure 9.26 Italy: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.27 Spain: Liquid Biopsy Market, 2017-2028
Figure 9.28 Spain: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.29 Rest-of-Europe: Liquid Biopsy Market, 2017-2028
Figure 9.30 Asia-Pacific: Liquid Biopsy Market, 2017-2028
Figure 9.31 Asia-Pacific: Market Dynamics
Figure 9.32 Asia Pacific: Liquid Biopsy Market (by Country), 2017-2028
Figure 9.33 China: Liquid Biopsy Market, 2017-2028
Figure 9.34 China: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.35 Japan: Liquid Biopsy Market, 2017-2028
Figure 9.36 Japan: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.37 India: Liquid Biopsy Market, 2017-2028
Figure 9.38 India: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.39 Australia: Liquid Biopsy Market, 2017-2028
Figure 9.40 Australia: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.41 South Korea: Liquid Biopsy Market, 2017-2028
Figure 9.42 South Korea: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.43 Singapore: Liquid Biopsy Market, 2017-2028
Figure 9.44 Singapore: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.45 Rest-of-Asia Pacific: Liquid Biopsy Market, 2017-2028
Figure 9.46 Latin America: Liquid Biopsy Market, 2017-2028
Figure 9.47 Latin America: Market Dynamics
Figure 9.48 Latin America: Liquid Biopsy Market (by Country), 2017-2028
Figure 9.49 Brazil: Liquid Biopsy Market, 2017-2028
Figure 9.50 Brazil: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.51 Mexico: Liquid Biopsy Market, 2017-2028
Figure 9.52 Mexico: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.53 Saudi Arabia: Liquid Biopsy Market, 2017-2028
Figure 9.54 Saudi Arabia: Liquid Biopsy Market (by Therapeutic Application), 2017-2028
Figure 9.55 Rest-of-Latin America and Middle East: Liquid Biopsy Market, 2017-2028
Figure 9.56 Rest-of-the-World: Liquid Biopsy Market, 2017-2028
Figure 10.1 Shares of Key Company Profiles
Figure 10.2 Abcodia Ltd.: Product Offerings for Global Liquid Biopsy Market
Figure 10.3 Abcodia Ltd.: SWOT Analysis
Figure 10.4 Adaptive Biotechnologies: Product Offerings for Global Liquid Biopsy Market
Figure 10.5 Adaptive Biotechnologies: SWOT Analysis
Figure 10.6 ANGLE plc: Product Offerings for Global Liquid Biopsy Market
Figure 10.7 ANGLE plc: Overall Financials, 2015-2017
Figure 10.8 ANGLE plc: Revenue (by Region), 2016 and 2017
Figure 10.9 ANGLE plc: R&D Expense, 2015-2017
Figure 10.10 ANGLE plc: Revenue Forecast, 2015-2020
Figure 10.11 ANGLE plc: Global Presence
Figure 10.12 ANGLE plc: SWOT Analysis
Figure 10.13 Biocept, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.14 Biocept, Inc.: Overall Financials, 2015-2017
Figure 10.15 Biocept, Inc.: R&D Expense, 2015-2017
Figure 10.16 Biocept, Inc.: Revenue Forecast, 2015-2020
Figure 10.17 Biocept, Inc.: SWOT Analysis
Figure 10.18 Bio-Rad Laboratories, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.19 Bio-Rad laboratories, Inc.: Overall Financials, 2015-2017
Figure 10.20 Bio-Rad Laboratories, Inc.: Revenue (by Business Segment), 2015-2017
Figure 10.21 Bio-Rad Laboratories, Inc.: Revenue (by Region), 2015-2017
Figure 10.22 Bio-Rad Laboratories, Inc.: R&D Expense, 2015-2017
Figure 10.23 Bio-Rad Laboratories, Inc.: Revenue Forecast, 2015-2020
Figure 10.24 Bio-Rad Laboratories, Inc.: Global Presence
Figure 10.25 Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 10.26 Cynvenio Biosystems, Inc.: Overall Product Portfolio
Figure 10.27 Cynvenio Biosystems, Inc.: SWOT Analysis
Figure 10.28 Chronix Biomedical: Product Offerings for Global Liquid Biopsy Market
Figure 10.29 Chronix Biomedical: SWOT Analysis
Figure 10.30 Epic Sciences, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.31 Epic Sciences, Inc.: SWOT Analysis
Figure 10.32 F. Hoffmann-La Roche AG: Product Offerings for Global Liquid Biopsy Market
Figure 10.33 F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
Figure 10.34 F. Hoffmann-La Roche AG: Revenue (by Business Segment), 2015-2017
Figure 10.35 F. Hoffmann-La Roche Ltd.: Revenue (by Diagnostics Sub-division), 2015-2017
Figure 10.36 F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017
Figure 10.37 F. Hoffmann-La Roche AG: R&D Expense, 2015-2017
Figure 10.38 F. Hoffmann-La Roche AG: Revenue Forecast, 2015-2020
Figure 10.39 F. Hoffmann-La Roche AG: Global Presence
Figure 10.40 F. Hoffmann-La Roche AG: SWOT Analysis
Figure 10.41 GUARDANT HEALTH, INC.: Product Offerings for Global Liquid Biopsy Market
Figure 10.42 GUARDANT HEALTH, INC.: SWOT Analysis
Figure 10.43 Illumina, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.44 Illumina, Inc.: Overall Financials, 2015-2017
Figure 10.45 Illumina, Inc.: Revenue (by Business Segment), 2015-2017
Figure 10.46 Illumina, Inc.: Revenue (by Region), 2015-2017
Figure 10.47 Illumina, Inc.: R&D Expense, 2015-2017
Figure 10.48 Illumina, Inc.: Revenue Forecast, 2015-2020
Figure 10.49 Illumina, Inc.: Global Presence
Figure 10.50 Illumina, Inc.: SWOT Analysis
Figure 10.51 MDxHealth, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.52 MDxHealth, Inc.: Overall Financials, 2015-2017
Figure 10.53 MDxHealth, Inc.: R&D Expanse, 2015-2017
Figure 10.54 MDxHealth, Inc.: Revenue Forecast, 2015-2017
Figure 10.55 MDxHealth, Inc.: Global Presence
Figure 10.56 MDxHealth, Inc.: SWOT Analysis
Figure 10.57 Menarini Silicon Biosystems, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.58 Menarini Silicon Biosystems, Inc.: SWOT Analysis
Figure 10.59 Myriad Genetics, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.60 Myriad Genetics, Inc.: Overall Financials, 2015-2017
Figure 10.61 Myriad Genetics, Inc.: Revenue (by Business Segment), 2015-2017
Figure 10.62 Myriad Genetics, Inc.: Revenue (by Region), 2015-2017
Figure 10.63 Myriad Genetics, Inc.: R&D Expense, 2015-2017
Figure 10.64 Myriad Genetics, Inc.: Revenue Forecast, 2015-2020
Figure 10.65 Myriad Genetics, Inc.: Global Presence
Figure 10.66 Myriad Genetics, Inc.: SWOT Analysis
Figure 10.67 Natera, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.68 Natera, Inc.: Overall Financials, 2015-2017
Figure 10.69 Natera, Inc.: Revenue (by Region), 2015-2017
Figure 10.70 Natera, Inc.: R&D Expense, 2015-2017
Figure 10.71 Natera, Inc.: Revenue Forecast, 2015-2020
Figure 10.72 Natera, Inc.: Global Presence
Figure 10.73 Natera, Inc.: SWOT Analysis
Figure 10.74 NeoGenomics Laboratories, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.75 NeoGenomics Laboratories, Inc.: Overall Financials, 2015-2017
Figure 10.76 NeoGenomics Laboratories, Inc.: Revenue (by Business Segment), 2015-2017
Figure 10.77 NeoGenomics Laboratories, Inc.: R&D Expense, 2015-2017
Figure 10.78 NeoGenomics Laboratories, Inc.: Revenue Forecast, 2015-2020
Figure 10.79 NeoGenomics Laboratories, Inc.: Global Presence
Figure 10.80 NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 10.81 Personal Genome Diagnostics, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.82 Personal Genome Diagnostics, Inc.: SWOT Analysis
Figure 10.83 Qiagen N.V.: Product Offerings for Global Liquid Biopsy Market
Figure 10.84 Qiagen N.V.: Overall Financials, 2015-2017
Figure 10.85 Qiagen N.V.: Revenue (by Business Segment), 2015-2017
Figure 10.86 Qiagen N.V.: Revenue (by Region), 2015-2017
Figure 10.87 Qiagen N.V.: R&D Expense, 2015-2017
Figure 10.88 Qiagen N.V.: Revenue Forecast, 2015-2020
Figure 10.89 Qiagen N.V.: Global Presence
Figure 10.90 Qiagen N.V.: SWOT Analysis
Figure 10.91 Resolution Bioscience, Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.92 Resolution Bioscience, Inc.: SWOT Analysis
Figure 10.93 Sysmex Corporation: Product Offerings for Global Liquid Biopsy Market
Figure 10.94 Sysmex Corporation: Overall Financials, 2015-2017
Figure 10.95 Sysmex Corporation: Revenue (by Business Segment), 2016 and 2017
Figure 10.96 Sysmex Corporation: Revenue (by Business Segment), 2015
Figure 10.97 Sysmex Corporation: Revenue by Product Type (2015-2017)
Figure 10.98 Sysmex Corporation: Revenue (by Region), 2015-2017
Figure 10.99 Sysmex Corporation: R&D Expense, 2015-2017
Figure 10.100 Sysmex Corporation: Revenue Forecast, 2015-2020
Figure 10.101 Sysmex Corporation: Global Presence
Figure 10.102 Sysmex Corporation: SWOT Analysis
Figure 10.103 Thermo Fisher Scientific Inc.: Product Offerings for Global Liquid Biopsy Market
Figure 10.104 Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017
Figure 10.105 Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2015-2017
Figure 10.106 Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017
Figure 10.107 Thermo Fisher Scientific Inc.: R&D Expense, 2015-2017
Figure 10.108 Thermo Fisher Scientific Inc.: Revenue Forecast, 2015-2020
Figure 10.109 Thermo Fisher Scientific Inc.: Global Presence
Figure 10.110 Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 11.1 Global Liquid Biopsy: Market Segmentation
Figure 11.2 Global Liquid Biopsy Market Segmentation
Figure 11.3 Primary Research
Figure 11.4 Secondary Research
Figure 11.5 Data Triangulation
Figure 11.6 Top-down Approach (Segment-wise Analysis)
Figure 11.7 Bottom-up Approach (Segment-wise Analysis)
Figure 11.8 Assumptions and Limitations
Figure 11.9 Considered Factors for Data Prediction and Modelling
